“Initiation of dosing in our Phase 1b clinical trial represents an important step in the clinical development of GT-02287 and in Gain’s mission to deliver a disease-modifying therapy to people ...

Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today reported financial results for the ...

Orphan Drug Designation follows positive Phase 1 data presented at the 12th International Workshop on Waldenström MacroglobulinemiaFirst-in-class ...

Tenaya Therapeutics, Inc. announced the initiation of dosing in Cohort 2 of its MyPEAK™-1 Phase 1b/2 clinical trial for TN-201, aimed at treating MYBPC3-associated hypertrophic cardiomyopathy (HCM).

Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the ...

Nuvectis Pharma, Inc. ("Nuvectis”, "Company”), a biopharmaceutical company focused on the development of innovative precision ...

Additional Phase 2 data for vilastobart,a tumor-activated, Fc-enhanced anti-CTLA-4, in combination with atezolizumab in patients with MSS CRC ...

AUSTIN, TX & PHILADELPHIA, PA — Faeth Therapeutics and The GOG Foundation, Inc. have announced a significant milestone in the ...

Updated Phase 1 data for ELVN-001 expected mid-2025 as positive enrollment momentum continues Expected monotherapy and combination data from the ELVN-002 Phase 1 trials ...

in the ADPORT-601 Phase 1b clinical trial. This follows a previous pause due to funding concerns. The resumption of enrollment highlights the encouraging safety data observed in earlier cohorts.